Claims for Patent: 8,703,806

Summary for Patent: 8,703,806

Title:	Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
Abstract:	Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.
Inventor(s):	Vehring; Reinhard (Edmonton, CA), Hartman; Michael Steven (Millbrae, CA), Lechuga-Ballesteros; David (San Jose, CA), Smith; Adrian Edward (Emerald Hills, CA), Joshi; Vidya B. (Redwood City, CA), Dwivedi; Sarvajna Jumar (Redwood City, CA)
Assignee:	Pearl Therapeutics, Inc. (Redwood City, CA)
Application Number:	13/692,904
Patent Claims:	1. A method for treating a pulmonary disease or disorder in a patient, the method comprising: providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension, the co-suspension comprising: a suspension medium comprising a pharmaceutically acceptable propellant free of additional constituents; a first species of respirable active agent particles comprising a pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate in crystalline form as a first respirable active agent; one or more additional respirable active agent comprising one or more additional respirable active agent selected from the group consisting of a short-acting beta agonist, a long-acting and ultra long-acting .beta..sub.2 adrenergic receptor agonist (LABA), a corticosteroid, an anti-inflammatory, an anti-tussive, a bronchodilator, and a muscarinic antagonist; and a plurality of respirable suspending particles, wherein the total mass of the respirable suspending particles exceeds the total mass of the first respirable active agent and the one or more additional respirable active agent, the plurality of suspending particles are formed of a material that is substantially insoluble in the suspension medium, and the first respirable active agent and the one or more additional respirable active agent co-locate with the plurality of suspending particles to form a co-suspension; and administering a therapeutically effective amount of the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate and the one or more additional respirable active agent to the patient, wherein said administering comprises delivering the co-suspension to the patient by actuating the metered dose inhaler. 2. The method of claim 1, wherein the pulmonary disease or disorder is selected from the group consisting of asthma, COPD, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary inflammation experienced with cystic fibrosis, and pulmonary obstruction experienced with cystic fibrosis. 3. The method of claim 1, wherein delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate of no more than 20 .mu.g per actuation of the metered dose inhaler. 4. The method of claim 3, wherein delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate of no more than 10 .mu.g per actuation of the metered dose inhaler. 5. The method of claim 4, wherein said administration results in an increase in FEV.sub.1 in the patient of at least 70 mL within 1.0 hour or less. 6. The method of claim 3, wherein said administration results in an increase in FEV.sub.1 in the patient of at least 100 mL within 1.0 hour or less. 7. The method of claim 6, wherein delivering the co-suspension composition to the patient further results in a clinically significant increase in inspiratory capacity (IC) in the patient. 8. The method of claim 3, wherein delivering the co-suspension composition to the patient results in an increase in FEV.sub.1 in the patient of at least 100 mL within 0.5 hour or less. 9. The method of claim 3, wherein delivering the co-suspension composition to the patient by actuating the metered dose inhaler comprises delivering the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate to the patient at a delivered dose uniformity of .+-.25% or better, throughout emptying of the canister. 10. The method of claim 1, wherein providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension comprises providing a co-suspension comprising suspending particles formed of a dry particulate phospholipid. 11. The method of claim 10, wherein providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension comprises providing a co-suspension comprising suspending particles formed of 1,2-distearoyl-sn-Glycero-3-phosphocholine. 12. The method of claim 1, wherein providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first respirable active agent and the one or more additional respirable active agent ranging from about 1 and up to about 200. 13. The method of claim 12, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first respirable active agent and the one or more additional respirable active agent selected from the ranges of between about 10 and about 200, between about 60 and about 200, between about 15 and about 60, and between about 15 and about 170. 14. The method of claim 12, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first respirable active agent and the one or more additional respirable active agent of between about 15 and about 60. 15. The method of claim 1, wherein the co-suspension contained within the canister comprises a second respirable active agent comprising a LABA active agent selected from the group consisting of bambuterol, clenbuterol, formoterol, salmeterol, carmoterol, milveterol, indacaterol, saligenin- or indole- containing and adamantyl-derived .beta..sub.2 agonists and pharmaceutically acceptable salts, esters, or isomers thereof. 16. The method of claim 15, wherein the second respirable active agent comprises a pharmaceutically acceptable salt, ester, or isomer of formoterol. 17. The method of claim 16, wherein said delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate of no more than 10 .mu.g per actuation of the metered dose inhaler. 18. The method of claim 17, wherein said delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of formoterol of no more than 5 .mu.g per actuation of the metered dose inhaler. 19. The method of claim 17, wherein said delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of formoterol of between about 0.5 .mu.g and 30 .mu.g per actuation of the metered dose inhaler. 20. The method of claim 17, wherein providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first and second respirable active agents ranging from above 1 and up to about 200. 21. The method of claim 20, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first and second respirable active agents selected from the ranges of between about 10 and about 200, between about 60 and about 200, between about 15 and about 60, and between about 15 and about 170. 22. The method of claim 17, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first and second respirable active agents of between about 15 and about 60 and said delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of formoterol of no more than 5 .mu.g per actuation of the metered dose inhaler. 23. The method of claim 22, wherein the pulmonary disease or disorder is selected from the group consisting of asthma, COPD, allergic rhinitis, sinusitis, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pulmonary hypertension, pulmonary inflammation experienced with cystic fibrosis, and pulmonary obstruction experienced with cystic fibrosis. 24. The method of claim 23, wherein the pulmonary disease or disorder is COPD. 25. The method of claim 16, wherein said delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate of no more than 20 .mu.g per actuation of the metered dose inhaler. 26. The method of claim 25 wherein said delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of formoterol of no more than 2.5 .mu.g per actuation of the metered dose inhaler. 27. The method of claim 25, wherein said delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of formoterol of no more than 5 .mu.g per actuation of the metered dose inhaler. 28. The method of claim 25, wherein said delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of formoterol of between about 0.5 .mu.g and 30 .mu.g per actuation of the metered dose inhaler. 29. The method of claim 1, wherein the co-suspension contained within the canister comprises a second respirable active agent comprising a corticosteroid active agent selected from the group consisting of beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone, methyl-prednisolone, mometasone, prednisone, trimacinolone and any pharmaceutically acceptable salts, esters, or isomers thereof. 30. The method of claim 29, wherein providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first respirable active agent, and the one or more additional respirable active agent ranging from above 1 and up to about 200. 31. The method of claim 30, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first respirable active agent and the one or more additional respirable active agent ranging up to about 1.5, up to about 5, up to about 10, and up to about 15. 32. The method of claim 31, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first respirable active agent and the one or more additional respirable active agent selected from up to about 5. 33. The method of claim 32, wherein the corticosteroid active agent is selected from the group consisting of budesonide, fluticasone, ciclesonide and mometasone. 34. The method of claim 1, wherein, in addition to the first species of respirable active agent particles, the co-suspension contained within the canister comprises a second respirable active agent comprising a LABA active agent selected from the group consisting of formoterol and pharmaceutically acceptable salts, esters, or isomers thereof, and a third respirable active agent comprising a corticosteroid active agent selected from the group consisting of beclomethasone. budesonide, ciclesonide, flunisolide, fluticasone, methyl-prednisolone, mometasone, prednisone, trimacinolone and any pharmaceutically acceptable salts, esters, or isomers thereof. 35. The method of claim 34, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the first respirable active agent and the one or more additional respirable active agent ranging up to about 5 and said delivering of the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate of no more than 10 .mu.g per actuation of the metered dose inhaler and a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of formoterol of no more than 5 .mu.g per actuation of the metered dose inhaler. 36. The method according to any one of claims 35, wherein the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1-hydroxynaphthalene-2-carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate, and benzenesulfonate salts and the pharmaceutically acceptable salt, ester, or isomer of formoterol is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acid salts. 37. The method of claim 36, wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, and iodide salts and the pharmaceutically acceptable salt of formoterol is formoterol fumarate. 38. The method according to claim 37, wherein the pharmaceutically acceptable salt of glycopyrrolate is 3-[(cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. 39. The method according to claim 38, wherein the formoterol fumarate comprises respirable crystalline particles of formoterol fumarate. 40. A method for respiratory delivery of a therapeutically effective amount of at least two active agents to a patient, the method comprising: providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension, the co-suspension comprising: a suspension medium comprising a pharmaceutically acceptable propellant free of additional constituents; a plurality of respirable active agent particles comprising a pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate in crystalline form as a first respirable active agent; one or more additional species of respirable active agent comprising one or more additional respirable active agents selected from the group consisting of a short-acting beta agonist, a long-acting and ultra long-acting .beta..sub.2 adrenergic receptor agonist (LABA), a corticosteroid, an anti-inflammatory, an anti-tussive, a bronchodilator, and a muscarinic antagonist; and a plurality of respirable suspending particles, wherein the plurality of respirable suspending particles are formed of a dry particulate phospholipid material that is substantially insoluble in the suspension medium and the plurality of respirable active agent particles associate with the plurality of suspending particles to form a co-suspension; and administering a therapeutically effective amount of the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate and the one or more additional species of respirable active agents to the patient, wherein said administering comprises delivering the co-suspension to the patient by actuating the metered dose inhaler. 41. The method of claim 40, wherein the co-suspension contained within the canister comprises a second species of respirable active agent comprising a LABA active agent selected from the group consisting of bambuterol, clenbuterol, formoterol, salmeterol, carmoterol, milveterol, indacaterol, saligenin- or indole- containing and adamantyl-derived .beta..sub.2 agonists and pharmaceutically acceptable salts, esters, or isomers thereof. 42. The method of claim 41, wherein the second species of respirable active agent comprises a pharmaceutically acceptable salt, ester, or isomer of formoterol. 43. The method of claim 42, wherein delivering the co-suspension composition to the patient comprises administering a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of formoterol of up to about 5 .mu.g per actuation of the metered dose inhaler and a delivered dose of the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate of up to about 10 .mu.g per actuation of the metered dose inhaler. 44. The method of claim 42, wherein the co-suspension contained within the canister comprises a third species of respirable active agent comprising a corticosteroid active agent selected from the group consisting of beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone, methyl-prednisolone, mometasone, prednisone, trimacinolone and any pharmaceutically acceptable salts, esters, or isomers thereof. 45. The method of claim 42, wherein providing a metered dose inhaler comprising a canister containing a pharmaceutically acceptable co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the different respirable active agents ranging from above 1 and up to about 200. 46. The method of claim 45, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the different respirable active agents selected from the ranges of between about 10 and about 200, between about 60 and about 200, between about 15 and about 60, and between about 15 and about 170. 47. The method of claim 46, wherein providing the co-suspension comprises providing a co-suspension exhibiting a ratio of total mass of the suspending particles to total mass of the different respirable active agents of between about 15 and about 60. 48. The method of claim 47, wherein delivering the active agents to the patient results in the patient experiencing an increase in baseline FEV.sub.1 of at least 200 ml within 1 hour or less, with said baseline FEV.sub.1 being measured prior to delivery of the co-suspension composition. 49. The method of claim 42, wherein delivering the active agents to the patient results in the patient experiencing a 10% or greater increase in baseline FEV.sub.1 within a period of time selected from 1 hour or less, 1.5 hours or less, 2 hours or less, and 2.5 hours or less, with said baseline FEV.sub.1 being measured prior to delivery of the co-suspension composition. 50. The method of claim 47, wherein delivering the active agents to the patient results in the patient experiencing a 10% or greater increase in baseline FEV.sub.1 within 1 hour or less, with said baseline FEV.sub.1 being measured prior to delivery of the co-suspension composition. 51. The method of claim 42, wherein delivering the active agents to the patient results in the patient experiencing an increase in baseline FEV.sub.1 of at least 200 ml within a period of time selected from 1 hour or less, 1.5 hours or less, 2 hours or less, and 2.5 hoursor less, with said baseline FEV.sub.1 being measured prior to delivery of the co-suspension composition. 52. The method of claim 47, wherein delivering the active agents to the patient results in the patient experiencing a total increase in baseline FEV.sub.1 of at least 150 ml within 1 hour or less, with said baseline FEV.sub.1 being measured prior to delivery of the co-suspension composition. 53. The method of claim 42, wherein delivering the active agents to the patient results in the patient experiencing a total increase in baseline FEV.sub.1 of at least 150 ml within a period of time selected from 1 hour or less, 1 .5 hours or less, 2 hours or less, and 2.5 hours or less, with said baseline FEV.sub.1 being measured prior to delivery of the co-suspension composition. 54. The method according to any one of claims 16-22 and 34, wherein the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1-hydroxynaphthalene-2-carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate, and benzenesulfonate salts and the pharmaceutically acceptable salt, ester, or isomer of formoterol is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acid salts. 55. The method of claim 54, wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, and iodide salts and the pharmaceutically acceptable salt of formoterol is formoterol fumarate. 56. The method of claim 55, wherein the pharmaceutically acceptable salt of glycopyrrolate is 3-[(cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. 57. The method of claim 56, wherein the formoterol fumarate comprises respirable crystalline particles of formoterol fumarate. 58. The method according to any one of claims 42-52, wherein the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1-hydroxynaphthalene-2-carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate, and benzenesulfonate salts and the pharmaceutically acceptable salt, ester, or isomer of formoterol is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, fumaric, maleic, acetic, lactic, citric, tartaric, ascorbic, succinic, glutaric, gluconic, tricarballylic, oleic, benzoic, p-methoxybenzoic, salicylic, o- and p-hydroxybenzoic, p-chlorobenzoic, methanesulfonic, p-toluenesulfonic and 3-hydroxy-2-naphthalene carboxylic acid salts. 59. The method according to claim 58, wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, and iodide salts and the pharmaceutically acceptable salt of formoterol is formoterol fumarate. 60. The method according to claim 59, wherein the pharmaceutically acceptable salt of glycopyrrolate is 3-[(cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. 61. The method according to claim 60, wherein the formoterol fumarate comprises respirable crystalline particles of formoterol fumarate. 62. The method according to any one of claims 1-52, wherein the pharmaceutically acceptable salt, ester, or isomer of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1-hydroxynaphthalene-2-carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate, and benzenesulfonate salts. 63. The method according to claim 62, wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, and iodide salts and the pharmaceutically acceptable salt of formoterol is formoterol fumarate. 64. The method according to claim 62, wherein the pharmaceutically acceptable salt of glycopyrrolate is 3-[(cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide.